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The diagnostic and prognostic importance of recurrent chromosomal aberrations in systemic B cell lymphoma is
well documented. In contrast, limited data exist on genetic changes in primary cutaneous B cell lymphoma. In this
study we investigated chromosomal aberration patterns in two types of primary cutaneous B cell lymphoma with a
different clinical behavior. Twenty-two primary cutaneous B cell lymphomas, including nine follicle center cell
lymphomas and 13 large B cell lymphomas of the leg, were analyzed by comparative genomic hybridization and in
part by ﬂuorescence in situ hybridization. The most frequent imbalances detectable were gains in 18q (eight of 22),
1q (six of 22), 7 (six of 22), 12q (six of 22), or Xp (four of 22), and losses in 6q (four of 22). In contrast to large B cell
lymphomas of the leg, primary cutaneous follicle center cell lymphomas had fewer imbalances and lacked
translocations affecting the IGH locus. Gains in 18q (eight of 13) and losses in 6q (four of 13) as well as breakpoints
within the IGH locus (six of 11) were restricted to the large B cell lymphomas of the leg subtype. Translocation t(14;
18) was excluded in 16 primary cutaneous B cell lymphomas of both subtypes that were studied by ﬂuorescence in
situ hybridization. These results suggest that primary cutaneous follicle center cell lymphoma and large B cell
lymphoma of the leg are characterized by different chromosomal aberration patterns, which in part might determine
the different clinical course of these malignancies.
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Primary cutaneous B cell lymphomas (PCBCL) are a
heterogeneous group of lymphomas, manifesting them-
selves primarily in the skin. Recently, the European
Organization for Research and Treatment of Cancer
(EORTC) proposed a classification of these heterogeneous
cutaneous malignancies that, besides histologic and im-
munophenotypical features, emphasizes their particular
clinical characteristics (Willemze et al, 1997).
Primary cutaneous follicle center cell lymphoma
(PCFCCL) is the most frequent type of indolent PCBCL.
These lymphomas generally present with skin lesions on the
head or trunk. In contrast, large B cell lymphoma of the leg
(LBCLL) typically presents itself at the lower extremity and
has a poorer clinical outcome. The 5 y survival rate of
LBCLL is 58% in contrast to more than 95% in PCFCCL
(Vermeer et al, 1996; Grange et al, 2001).
Grouping PCBCL into the main categories PCFCCL and
LBCLL based on the site of presentation as proposed by the
EORTC has been much disputed. So far expression of
BCL2 has been shown to be the only molecular difference
between these subtypes as it was found more frequently in
LBCLL than in PCFCCL or other subtypes of PCBCL
(Geelen et al, 1998; Grange et al, 2001). To date no other
studies have focused on other molecular differences in
these subtypes of PCBCL.
In contrast, in systemic B cell lymphomas typical
aberration patterns have been described for the different
subtypes and genetic analysis has become an important
tool for their differential diagnosis. Additionally, in certain
types of lymphoma chromosomal aberrations may also
carry prognostic significance (Tilly et al, 1994; Rickert et al,
1999; Schlegelberger et al, 1999; Chaganti et al, 2000; Ott
et al, 2002). Consequently, for these lymphomas character-
istic genetic markers have been included in the recently
published WHO classification (Jaffe et al, 2001).
Surprisingly, so far there only exists one very recent
study on chromosomal changes in PCBCL (Mao et al,
2002). Using comparative genomic hybridization (CGH) and
fluorescence in situ hybridization (FISH) we have looked for
differences in chromosomal aberration patterns in the two
prognostic different subtypes of PCBCL, classified as
PCFCCL and LBCLL according to EORTC criteria.
Results
CGH At initial diagnosis, chromosomal imbalances were
detected in 13 of the 22 cutaneous B cell lymphomas (Fig
Abbreviations: CGH, comparative genomic hybridization; EORTC,
European Organization for Research and Treatment of Cancer;
FISH, fluorescence in situ hybridization; LBCLL, large B cell
lymphoma of the leg; PCBCL, primary cutaneous B cell lymphoma;
PCFCCL, primary cutaneous follicle center cell lymphoma
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1a, Table I). Only considering those biopsies that were taken
at the time of primary diagnosis, low copy number gains
(n¼ 43) were more frequent than losses (n¼15). High-level
amplifications in 2p13p15 and 18q were detected in one
case each (Fig 1b, c). At initial diagnosis, the most frequent
aberrations in the whole group were gains of 18q (eight of
22), 1q (six of 22), 7 (six of 22), 12q (six of 22), or Xp (four of
22), and losses in 6q (four of 22).
The median number of all imbalances per PCBCL was
two (range 0–9). At initial diagnosis, six of nine PCFCCL but
only three of 13 LBCLL had no imbalances detectable by
CGH. There was a strong trend (p¼0.06) towards a lower
number of imbalances in PCFCCL (median 0, range 0–8)
compared to LBCLL (median 3, range 0–9). In general, gains
predominated over losses (p¼0.02 for all PCBCL, p¼0.04
for LBCLL) (Table II).
The pattern of imbalances differed in the two groups of
PCBCL (Table I). The only recurrent imbalances in PCFCCL
were gains of chromosomes 2p and 12q present each in
two of nine cases. Whereas gain at chromosome 1q was
seen in only one PCFCCL, five of 13 LBCLL had this
aberration. The most frequent imbalances in the complete
series were gains of 18q, which were restricted to LBCLL
(eight of 13 cases; p¼ 0.006 for LBCLL versus PCFCCL).
Similarly, losses in 6q were exclusively found in LBCLL
(p¼ 0.115). Remarkably, three of the four LBCLL with a loss
in 6q have died of lymphoma and one has progressive
disease 6 mo after diagnosis.
In four cases two different biopsies were analyzed. Two
biopsies taken simultaneously at the time of the diagnosis
from different sites (LBCLL nos. 3 and 12) revealed identical
CGH patterns proving the same clone in both lesions (Table
I). In contrast in LBCLL nos. 4 and 6 subsequent biopsies
were taken after 3 and 2 y, respectively. The subsequent
biopsies differed in the number and partly in the pattern of
chromosomal changes (Table I).
FISH analyses FISH analyses aiming to investigate the
presence of t(14; 18) as well as to confirm CGH results were
performed in 18 lymphoma biopsies from 16 patients with
sufficient frozen material available. None of the five
PCFCCL studied by FISH showed evidence for an IGH
break, ruling out a t(14; 18)(q32; q21), which is known to be
characteristic for systemic follicular lymphoma. In contrast,
LBCLL samples from six of 11 patients contained a
significant number of interphase nuclei with a signal pattern
indicating a breakpoint within the IGH locus (PCFCCL
versus LBCLL, p¼0.093). The percentage of nuclei with a
signal pattern indicating an IGH break in these LBCLL
ranged from 40% to 77%. Nevertheless, subsequent FISH
analysis with an assay specific for t(14; 18) lacked evidence
for an IGH-BCL2 juxtaposition in these LBCLL. Thus, the
t(14; 18) was not detected in any of the PCBCL under study.
All 16 PCBCL were also studied for the MLT locus at
18q21 by FISH. No breakpoints, which were characteristic
for MALT lymphomas, were observed but additional signals
indicating supernumerary copies of this locus were
detected in six LBCLL including one high-level amplifica-
tion. There was complete agreement with aberrations
detected by CGH for 18q and the copy number changes
detected by FISH for the MLT locus on 18q. Moreover, in all
those cases studied with the BCL2-specific probe, the copy
number of MLT was in the same range as that of the BCL2
locus, indicating the validity of the two methods.
In case LBCLL no. 1 the CGH ratio was only slightly
above the threshold, suggesting a gain of 7cenqter and
12cenqter. FISH with probes D7Z1 and D12Z1 revealed
three signals in 53% and 58% of the nuclei, respectively,
confirming the presence of these imbalances.
FISH on paraffin sections of case PCFCCL no. 1 showed
the candidate genes REL and BCL11A in 2p13–16 to be
contained in the amplification detected by CGH.
Thus, altogether there was an excellent complete
agreement between FISH data and CGH results confirming
the validity of the latter method. Moreover, the signal
patterns for the IGH locus suggested diploidy of the tumor
cells in all cases, which is of importance for the correct
interpretation of CGH findings. Finally, the percentage of
aberrant nuclei in FISH closely resembled that of the CD20
positive tumor cells in the sections (Tables I, III).
Discussion
In contrast to extracutaneous B cell lymphomas, in which
certain chromosomal aberrations are well known as
diagnostic and prognostic markers, so far there is only
one recent study investigating chromosomal imbalances in
subtypes of PCBCL (Mao et al, 2002). In that study
cutaneous lymphomas were classified according to the
WHO system, no breakpoints in the IGH locus were
analyzed, and no clinical data were presented. In our study,
we show that PCBCL of the PCFCCL and LBCLL subtypes
differ in the number and pattern of genomic imbalances as
well as in the presence of breakpoints in the IGH locus.
By CGH, we detected imbalances in 13 of the 22
cutaneous B cell lymphomas at initial diagnosis. In one
LBCLL lacking imbalances at initial diagnosis, we detected
changes in a subsequent biopsy. Eight cases including six
PCFCCL and two LBCLL showed no aberrations detectable
by CGH. As all samples included in this study consistently
contained more than 50% of tumor cells as demonstrated
by morphology, immunohistochemistry, and FISH, it is
highly unlikely that the lack of imbalances detectable by
CGH was caused by technical limitations (Larsen et al,
1999; Viardot et al, 2001).
By CGH we observed a strong trend towards a lower
average number of imbalances in PCFCCL than in LBCLL
(Table II). This finding is in line with findings in noncutaneous
B cell lymphomas, which have demonstrated the number of
chromosomal changes to be lower in indolent than in
aggressive lymphomas and correlated with the histologic
grade (Offit et al, 1991; Bea et al, 1999; Chaganti et al, 2000;
Horsman et al, 2001; Ott et al, 2002). Indeed, complexity of
the karyotype is one of the strongest adverse prognostic
factors in several subtypes of systemic B cell lymphomas.
Our data likewise suggest that the unfavorable course of
LBCLL compared to PCFCCL may be causally related to a
higher complexity of genetic changes. A similar trend was
found by Mao et al even though these authors included in
their analysis regions on several chromosomes that are
known to produce false results in CGH analyses, such as
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1p32pter, chromosome 19, and the Y chromosome. For
technical reasons this is not generally accepted (Kallioniemi
et al, 1994).
Only three of nine PCFCCL displayed chromosomal
imbalances by CGH with gains in 2p and 12q being
recurrent. In particular, the high-level amplification in
2p13–15 detected in PCFCCL no. 1 might indicate the
localization of an oncogene involved in the pathogenesis of
this subtype of PCFCCL. As demonstrated by FISH, two
oncogenes located in the chromosomal region 2p13–15, the
BCL11A and the REL gene, were amplified in this case.
Remarkably both genes have been suggested to be
implicated in B cell lymphomagenesis (Satterwhite et al,
2001; Martin-Subero et al, 2002). Notably, there is con-
siderable evidence that REL is frequently amplified in
lymphomas derived from germinal-center cells, e.g., folli-
cular lymphomas or germinal-center-cell-derived diffuse
large B cell lymphomas. This has been shown also by
real-time PCR, which is a powerful tool for the detection of
gene amplifications (Goff et al, 2000; Barth et al, 2001;
Rosenwald et al, 2002). It is intriguing to speculate that this
REL/nuclear factor k-B transcription factor might play a
prominent role in the development of PCFCCL.
In line with the majority of previous PCR-based studies
we could confirm the absence of the t(14; 18)(q32; q21) in
PCFCCL and in LBCLL by FISH. This translocation is the
hallmark of systemic follicular lymphoma, in PCFCCL but
also in LBCLL (Cerroni et al, 1994; Geelen et al, 1998; Child
et al, 2001; Franco et al, 2001; Hembury et al, 2002; Mirza
et al, 2002). Furthermore our work is the first to address
the question whether other translocations affecting the IGH
locus may play a role in cutaneous B cell lymphomas. We
demonstrated that translocations affecting the IGH locus
are infrequent in PCFCCL. In contrast, in LBCLL approxi-
mately half the cases showed evidence for breakpoints
within the IGH locus by FISH. The frequency of such
breakpoints in LBCLL is comparable to that described in
systemic diffuse large B cell lymphoma of noncutaneous
origin (Willis and Dyer, 2000; Siebert et al, 2001). The BCL2
gene could be excluded as translocation partner in the
LBCLL suggesting that the IGH locus shows similar
promiscuity to that described earlier for extracutaneous
primary large B cell lymphomas. Studies are ongoing to
characterize these changes.
Most interesting, also the pattern of genomic imbalances
as detected by CGH in our group of LBCLL resembled that
described for extracutaneous diffuse large B cell lympho-
mas (Monni et al, 1996; Werner et al, 1997; Rao et al, 1998).
The most frequent imbalance detected in LBCLL was a gain
in 18q present in eight of 13 cases. Gain of 18q is also one
of the most consistent imbalances in diffuse large B cell
lymphomas with primary nodal, gastrointestinal, or central
nervous system involvement (Barth et al, 1998; Montesinos-
Rongen et al, in press). Candidate target genes for these
Figure 1
(a) Summary of CGH data of nine PCFCCL (red
lines) and 13 LBCLL (green lines) at initial diagnosis.
Lines on the left indicate a loss of chromosomal
material; lines on the right indicate a gain
of material. Squares indicate an amplification of
chromosomal fragments of PCFCCL (red) and of
LBCLL (green). Each line indicates one aberration
detected in a single tumor. Chromosomal regions,
other than centromeric and telomeric regions, which
were also excluded from interpretation, are marked
gray. (b) CGH profile and fluorescence images of
chromosome 2 in PCFCCL no. 1 indicating high-
level amplification in 2p13–15. FISH analyses with
locus-specific probes reveal that the REL and the
BCL11A oncogenes, which are located in this
region, are amplified. This is indicated by clustering
of the red (BCL11A gene locus) and the green (REL
gene locus) fluorescing signals. (c) CGH profile and
fluorescence images of chromosome 18 in LBCLL
no. 10 indicating high-level amplification of the
complete long arm of chromosome 18 (upper part).
FISH with the distal MLT-specific probe (red signals)
on the same cases (lower panel). In contrast to the
nucleus on the left showing a regular signal
constellation, both cells on the right show multiple
and enlarged signals indicating amplification of
18q21.
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Table I. Results of the CGH and FISH analyses in PCBCL described according to the guidelines of ISCN
(Mitelman and Karger, 1995)
Patient no. CGH karyotype Interphase FISH
PCFCCL
1 rev ish enh(9q13–q21, 12q13–q15), amp(2p14–p15) n.d.
2 rev ish enh(1q21–q31, 2, 5p13–q23, 7, 12q14–q21, 14q11–q24, X), dim(4q32–qter) IGH  2, MLT  2
IGH prox sep IgH dist  0
3 – n.d.
4 – n.d.
5 – IGH  2, MLT  2
IGH prox sep IGH dist  0
6 rev ish dim(15q11–q15) IGH  2, MLT  2
IGH prox sep IGH dist  0
7 – IGH  2, MLT  2
IGH prox sep IGH dist  0
8 – IGH  2, MLT  2
IGH prox sep IGH dist  0
9 – n.d.
LBCLL
1 rev ish enh(7q, 12q, 18q12–qter) IGH  2, BCL2  3, MLT  3 (50.5%)
IGH prox sep IGH dist  1 (49%)
IGH con BCL2  0
2 rev ish enh(7p), dim(6q15–21, 6q23–25) IGH  2, MLT  2
IGH prox sep IGH dist  0
3a rev ish enh(18q), dim(17, 18p) IGH  2, BCL2  3, MLT  3 (50.5%)
IGH prox sep IGH dist  1 (50.5%)
IGH con BCL2  0
3b Identical to 3a IGH  2, BCL2  3, MLT  3 (54%)
IGH prox sep IGH dist  1 (50%)
IGH con BCL2  0
4a rev ish enh(1q21–q32), dim(6q) IGH  2, MLT  2
IGH prox sep IGH dist  0
4b rev ish enh(7), dim(6q, 20) n.d.
5 – IGH  2, MLT  2
IGH prox sep IGH dist  0
6a – n.d.
6b rev ish enh(17), dim(1p11–p21, 5q15–q23, 13q21–q31) IGH  2, MLT  2
IGH prox sep IGH dist  0
7 rev ish enh(1q, 2, 10, 11q14–qter, 12, 18, X) IGH  2, BCL2  3, MLT   3 (57%)
IGH prox sep IGH dist  1 (40%)
IGH con BCL2  0
8 rev ish enh(1q24–q31, 10, 18q), dim(6q22–q23, 17p) n.d.
9 – n.d.
10 rev ish enh(8), amp(18q) IGH  2, BCL2   3,MLT   3 (89.5%)
IGH prox sep IGH dist  1 (45%)
IGH con BCL2  0
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gains are BCL2 and MLT. In our series, FISH not only
confirmed the presence of 18q gains as detected by CGH
but also indicated these to consistently comprise both
genes, MLT and BCL2. Interestingly an amplification of the
BCL2 gene was recently also demonstrated in three out of
four primary cutaneous diffuse large B cell lymphomas by
array-CGH and in five out of 29 PCBCL by real-time PCR
(Mao et al, 2002). Together with our findings, their study also
underlines the relevance of BCL2 overexpression in PCBCL.
The most frequent loss detected in four out of 13 LBCLL
was deletion in 6q. Though our series is too small to
correlate genetic findings with the individual prognosis of
the patient, it should be emphasized that all four patients
with LBCLL with deletions in 6q ran a poor clinical course.
Also in extracutaneous lymphomas the loss of the long arm
of chromosome 6 is one of the most consistent adverse
prognostic factors. Deletions in 6q have been associated
with a poor prognosis in follicular lymphoma (Tilly et al,
1994; Viardot et al, in press) and diffuse large B cell
lymphomas arising systemically or in the central nervous
system (Offit et al, 1991; Rickert et al, 1999). Also in the
study of Mao et al the loss of chromosome 6q was
restricted to primary cutaneous diffuse large B cell
lymphoma.
In summary, we describe the existence of different
chromosomal aberration patterns in two clinical subtypes
of PCBCL. We were able to identify several recurrent
changes in PCFCCL and LBCLL and point to candidate
oncogene loci for the pathogenesis of these cutaneous
lymphomas. Analysis of larger series of these lymphomas
as well as expression studies have to prove the clinical and
biologic significance of the described chromosomal
changes.
Materials and Methods
Patients Nine patients with PCFCCL and 13 patients with LBCLL,
in which CD20þ neoplastic B cells constituted at least 50% of
total infiltrating lymphocytes, were selected for this study. All cases
met the criteria of the EORTC classification (Willemze et al, 1997).
In all cases lymphoma manifestations were restricted to the skin
at the time of diagnosis, as confirmed by complete staging
procedures including blood analyses, computerized tomography of
Table I. Continued
Patient no. CGH karyotype Interphase FISH
11 rev ish enh(1q24–qter, 4q33–qter, 6q12–q16, 7, 12, 18, X) IGH  2, BCL2  3, MLT   3 (60%)
IGH prox sep IGH dist  1 (40%)
IGH con BCL2  0
12a rev ish enh(3p14–qter, 7q21–q31, 12q14–q22, 18, Xp11–p21),
dim(6q22–ter, 15q11–21)
IGH  2, MLT   3 (70.5%)
IGH prox sep IGH dist  0
12b Identical to 12a IGH  2, MLT   3 (65.5%)
IGH prox sep IGH dist  0
13 rev ish enh(1q22–q32, 7q11–qter, 8q22–qter, 9, 18q),
dim(1q32–qter, 2p22–pter, 6p21–pter, 16q12–q23)
IGH  2, BCL2  4, MLT   3 (82%)
IGH prox sep IGH dist  1 (77%)
IGH con BCL2  0
n.d., not done; –, no aberration detected by CGH.
The percentage of interphase nuclei that contained an aberration is given in parentheses.
Table II. Frequency of imbalances detected in 22 PCBCL at initial diagnosis
Total PCBCL (n¼22) PCFCCL (n¼9) LBCLL (n¼ 13) p-value PCFCCL versus LBCLL
Total imbalances 60 12 48 0.06
(2; 0–9) (0; 0–8) (3; 0–9)
Gains/amplifications 45 10 35 0.06
(1; 0–7) (0; 0–7) (2; 0–7)
Losses 15 2 13 n.s.
(0; 0–4) (0; 0–1) (0; 0–4)
p-value gains/amplifications versus losses 0.02 n.s. 0.04
Median aberrations as well as range of aberrations per case are given in parentheses.
n.s., not significant/no trend (p40.1).
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the chest, ultrasound of lymph nodes and abdomen, and a
negative bone marrow histology.
The patients with a PCFCCL had skin lesions either in the head
and neck region (n¼ 5) or on their back (n¼ 4). Histology taken
at the time of diagnosis showed nodular or diffuse infiltrates
containing variable numbers (but always more than 50%) of
neoplastic small and large centrocytes and centroblasts. All but
one case of PCFCCL was analyzed for bcl-6 and in each case the
germinal center origin was demonstrated by a positive immuno-
histochemical staining for this marker. None of the nine cases
showed expression of the bcl-2 protein by immunohistologic
staining. After a median follow-up of 24 mo (range 6–49 mo) all
patients were still alive (Table III). The 13 patients with LBCLL
presented with nodular or tumorous skin lesions on one (n¼ 10) or
both (n¼ 3) legs. At the time of diagnosis, all these cases had the
histology of a diffuse large B cell lymphoma, and strong bcl-2
staining was observed in all 13 cases. Five of the 13 patients with
LBCLL died of lymphoma 12–73 mo after diagnosis (median
35 mo) (Table III).
In LBCLL nos. 3 and 12 the biopsies were obtained at the time
of diagnosis from two different skin lesions. In LBCLL nos. 4 and 6
a second biopsy was obtained at the time of disease progression/
relapse, 36 and 24 mo after diagnosis, respectively.
Biopsies and staining Either biopsy material was split or two
neighboring punch biopsies were taken from the same skin lesion.
For CGH one part of the material was snap frozen in liquid nitrogen,
and the other part was fixed in 4% buffered formalin, embedded,
and cut into 6 mm sections. Besides hematoxylin/eosin and Giemsa
staining, immunohistochemistry was performed using standard
immunoperoxidase techniques. All lymphoma samples were
stained for CD20 (clone L26, Dako, Denmark) and bcl-2 (clone
124, Dako). Percentage of CD20 positive cells was determined in
five high power fields (10  40) and grouped as 50%–70%,
470%–90%, and 490%. CD20 positive cells were counted in
skin sections that were located in close vicinity to those analyzed
by CGH and FISH. Eight of the nine PCFCCL were stained for bcl-6
(clone PG-B6p, Dako).
CGH Extraction of DNA was performed from 20 mm thick tissue
sections (n¼ 10) using the tissue-DNA extraction kit according to
the instructions of the manufacturer (Qiagen, Hilden, Germany).
CGH was performed as described previously (Kallioniemi et al,
1992) with a few modifications. For labeling, tumor DNA was nick-
translated using biotin-16-dUTPs (Roche, Mannheim, Germany).
Digoxigenin-11-dUTP-labeled normal reference DNA (Roche,
Mannheim, Germany) was used for cohybridization to slides with
Table III. Clinical and immunohistochemical data of the 22 PCBCL included in the study
Patient no. Sex/Age Localization First therapy Clinical course Follow-up time (mo) Bcl-2 CD20a
PCFCCL
1 M/48 Back RT Ao 35  470%–90%
2 M/58 Head RT Aþ 24  50%–70%
3 M/37 Back RT Ao 49  470%–90%
4 F/87 Back EX Ao 28  50%–70%
5 F/74 Head RT Aþ 6  50%–70%
6 F/61 Head RT Ao 9  470%–90%
7 M/58 Head EX Ao 20  50%–70%
8 M/59 Back RT Ao 6  470%–90%
9 M/64 Head RT Aþ 48  50%–70%
LBCLL
1 M/65 Two legs RT Aþ 3 þ 50%–70%
2 M/89 One leg CT DD 12 þ 490%
3 F/74 One leg CT Ao 12 þ 490%
4 F/82 One leg RT DD 38 þ 490%
5 F/73 One leg RT DD 18 þ 470%–90%
6 M/69 One leg RT DD 35 þ 470%–90%
7 F/77 One leg RT Ao 18 þ 470%–90%
8 F/75 One leg RT DD 73 þ 490%
9 M/47 Two legs RT, CT Ao 24 þ 490%
10 M/70 Two legs Inf Aþ 14 þ 470%–90%
11 F/53 One leg CT Aþ 6 þ 50%–70%
12 F/84 One leg CT Ao 6 þ 470%–90%
13 F/90 One leg RT Aþ 29 þ 490%
Age, patient age at diagnosis (y); M, male; F, female; RT, radiotherapy; EX, excision; CT, polychemotherapy; Inf, interferon-a; Aþ , alive with disease;
Ao, alive without disease; DD, dead of disease; follow-up time, time from diagnosis to latest follow-up or death.
aPercentage of CD20 positive infiltrating cells in the sample.
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metaphases from blood of sex-matched healthy donors. After 3 d
of hybridization at 371C, posthybridization washes were performed
and biotin-labeled tumor DNA was detected using avidinfluor-
fluorescein isothiocyanate (FITC). Reference DNA was detected by
antidigoxigeninrhodamine. For counterstaining 4,6-diamidino-
2-phenylindole was used. Digital image acquisition and image
analysis (Applied Imaging, Newcastle, UK) were performed as
described elsewhere (Kallioniemi et al, 1992). In each analysis, the
average green-to-red ratio was calculated for each chromosome
including at least 16 observations per autosome and eight
observations per sex chromosome. A gain of DNA sequences at
chromosomal regions was defined as a tumor-to-normal DNA ratio
of 1.20, and a loss of DNA sequences was defined as a tumor-to-
normal ratio of 0.80. Gains and losses are defined as low copy
number aberrations (1–4 copy numbers). A gain of material was
considered to be a high level amplification when the ratio was
above 2.0 or when there was a distinct hybridization band of the
FITC-labeled tumor DNA together with a calculated ratio showing
an overrepresentation of tumor DNA (Bentz et al, 1996; Bea et al,
1999). The chromosomal regions 1p32pter, 13p, 14p, 15p, 19,
21p, 22, telomeres, and constitutive heterochromatic regions at 1q,
9q, 16p, and Y, all known to produce false results by CGH, were
excluded from all analyses (Kallioniemi et al, 1994).
Interphase FISH Thick cryosections (60 mm) were mechanically
disaggregated and digested in a 5% pepsin solution for 5 min at
371C. Cytospins were prepared and the cells were fixed for 10 min
in 1% paraformaldehyde solution, dehydrated in graded ethanol
series, and dried at room temperature (Schlegelberger et al, 1999;
Montesinos-Rongen et al, in press). Detection of the translocation
t(14; 18) was performed as described recently (Gesk et al, 2001)
using in a first step directly labeled probes flanking the IGH gene
locus on chromosome 14 (LSI IGH Dual Color, Break Apart
Rearrangement Probe, Vysis, Downers Grove, IL). In cases with a
signal constellation that indicated a breakpoint affecting the IGH
locus, the LSI IGH/BCL2 Dual Color assay (Vysis) was applied to
directly prove the presence of a t(14; 18) translocation. Moreover, a
break apart assay for the MLT locus in 18q21 was applied using
directly labeled PAC clones (kindly provided by Dr Peter Marynen,
Leuven, Belgium) for the confirmation of copy number changes
detected by CGH on chromosome 18q (Dierlamm et al, 2000;
Montesinos-Rongen et al, in press). In case LBCLL no. 1 the
indirectly labeled a satellite probes D7Z1 and D12Z1 (Q-Biogene,
Heidelberg, Germany) mapping to the centromers of chromo-
somes 7 and 12 were applied to verify CGH results. Finally in case
PCFCCL no. 1 FISH was performed on paraffin sections pretreated
by high-pressure cooking using recently described probes for the
REL and BCL11A loci (Martin-Subero et al, 2002). These indirectly
labeled probes were visualized by FITCavidin and antidigoxigen-
inrhodamine (Q-Biogene). Results were evaluated using a fluor-
escence microscope (Axioplan, Zeiss, Jena, Germany) equipped
with a charge coupled device camera. In each cytospin sample at
least 200 nuclei were analyzed (Martin-Subero et al, in press).
Statistics The nonparametric Mann–Whitney U and Wilcoxon
tests as well as Fisher’s exact test were applied for comparisons
between PCFCLL and LBCLL, using the SPSS statistical package
version 11.0.
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